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Poliomyelitis Disease



First outbreak described in
the U.S. in 1843
More than 21,000 paralytic
cases reported in the U.S. in
1952
Global eradication within
this decade

•
•
•


Three serotypes of wild polio virus: 
WPV1
WPV2
WPV3
Minimal heterotypic immunity between serotypes
Rapidly inactivated by heat, chlorine, formaldehyde, and ultraviolet light
Poliovirus
 Entry into mouth
 Replication in pharynx and GI tract
 Hematologic spread to lymphatics and central nervous system
 Viral spread along nerve fibers
 Destruction of motor neurons
Poliomyelitis Pathogenesis
Racaniello VR. One hundred years of poliovirus pathogenesis. Virology 2006;344:9-16
Outcomes of Poliovirus Infection
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Asymptomatic Minor non-specific illness Aseptic meningitis Flaccid paralysis



Reservoir Human
Transmission Fecal-oralOral-oral possible
Communicability
Most infectious: 7-10 days before onset 
Virus present in stool            
3-6 weeks
Poliovirus Epidemiology
Poliomyelitis—United States, 1950-2011
Source: National Notifiable Disease Surveillance System, CDC 
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Poliomyelitis—United States, 1980-2010


1955 - Inactivated vaccine 
1963 - Trivalent OPV
1987 – Enhanced-potency  (IPV)
Poliovirus Vaccines
 Highly effective in producing immunity to poliovirus
•
•
≥90% of recipients immune after 2 doses
≥99% of recipients immune after 3 doses
 Duration of immunity not known with certainty
Inactivated Polio Vaccine

IPV Dose  Routinely Recommended at Minimum Interval 
1 2 months of age ----------
2 4 months of age 4 weeks 
3 6- 18 months of age 4 weeks 
4 4-6 years of age 6 months 
Childhood Polio Vaccination Schedule
 In the first 6 months of life, minimum age and minimum intervals are only 
recommended if the person is at risk of imminent exposure to circulating poliovirus 
 If 4 or more doses are administered before age 4 years, an additional dose should be 
administered at age 4 through 6 years and at least 6 months after the previous dose
 A fourth dose is not necessary if the third dose was administered at age 4 years or 
older and at least 6 months after the previous dose
–
Catch-up IPV Vaccination
www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 
 Only IPV is available in the United States
 If both OPV and IPV were administered as part of a series, the series should be
completed with IPV.  Any combination of 4 doses of OPV and IPV by 4 to 6 years of
age constitutes a complete series
 If only OPV doses were administered, and all doses were given prior to 4 years of
age, one dose of IPV should be given at 4 years or older, at least 4 weeks 6 months
after the last OPV dose
 Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements (tOPV
was used for routine poliovirus vaccination in all OPV-using countries until April 1, 
2016). 
Schedules that Include 
Both IPV and OPV

•
•
•
•
Single component vaccine - IPV (IPOL)
FOUR  polio-containing combination vaccine products: 
DTaP-IPV/Hib (Pentacel)
DTaP-HepB-IPV (Pediarix)
DTaP-IPV (Kinrix)
DTaP-IPV (Quadracel)
Poliovirus-containing Vaccine Products 

•
•

FDA-approved for: 
IPV doses 1 through 4 
Children 6 weeks through 4 years of age 
Use DTaP-IPV diluent to reconstitute the Hib component
DTaP-IPV/Hib (Pentacel)
Reminder: Only use 
the manufacturer’s 
supplied diluent
•
•
FDA-approved for:  
IPV doses 1 through 3 
Children 6 weeks through 6 years of age 
DTaP-HepB-IPV (Pediarix)
•
•

•
•
Kinrix
IPV dose 4 
Children 4 through 6 years of age 
Quadracel
IPV dose 4 or 5
4 through 6 years of age 
DTaP-IPV (Kinrix & Quadracel)
Vaccine Administration error: Do NOT use Quadracel to reconstitute 
the Hib component of Pentacel vaccine 

Routine vaccination of U.S. residents 18 years of age or older is not necessary or 
recommended
May consider vaccination of travelers to polio-endemic countries and selected lab 
workers 
Polio Vaccination of Adolescents and Adults
•


Use standard IPV schedule if possible 
0, 1-2 months, 6-12 months intervals
May separate first and second doses by 4 weeks if accelerated schedule needed 
The minimum interval between the second and third doses is 6 months
Polio Vaccination of Unvaccinated Adults 
•

•
–
•
Previously completed series
Administer 1 dose of IPV to those at risk
Incomplete series
Administer remaining doses in series based on immunization history
No need to restart a valid documented series 
Valid = minimum intervals met 
Polio Vaccination of Previously Vaccinated Adults

Severe allergic reaction to a vaccine component or following a prior dose of vaccine
Moderate to severe acute illness 
Contraindications and Precautions 

Local reactions 2.8% (pain, redness, swelling)
Severe reactions rare
IPV Adverse Reactions



Last case in the United States in 1979
Western Hemisphere certified polio-free in 1994
Last isolate of WPV2 was in India in October 1999
Global eradication goal 
Polio Eradication 



The number of worldwide reported cases has decreased from an estimated 350,000 in 1988 to 8 as of 
August 9, 2017
Afghanistan – 5 cases of WPV1
Pakistan – 3 cases of WPV1
Nigeria – Polio-free
Global Polio Efforts
http://www.polioeradication.org
http://polioeradication.org/polio-today/polio-now/this-week/
Additional Polio Resources


Polio Eradication:  www.cdc.gov/polio/
Polio Infection:  www.cdc.gov/vaccines/vpd/polio/index.html
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Haemophilus influenzae Type b and Hib Vaccine
National Center for Immunization & Respiratory Diseases Immunization Services Division




Severe bacterial infection, particularly among infants
Aerobic gram-negative bacteria
Polysaccharide capsule 
6 different serotypes (a-f) of polysaccharide capsule
95% of invasive disease caused by type b (prevaccine era)
Haemophilus influenzae


Formerly the leading cause of bacterial meningitis among children younger than 5 
years of age
Approximately 1 in 200 children developed invasive Hib disease
Almost all infections among children younger than 5 years
Impact of Haemophilus influenzae Type b Disease
Haemophilus influenzae Type b
Clinical Manifestations*
*Prevaccine era
Bacteremia
2%
Cellulitis
6%
Arthritis
8%
Osteomyelitis
2%
Pneumonia
15%
Epiglottitis
17%
Meningitis
50%
Hib facial cellulitis



Reservoir Human asymptomatic carriers
Transmission Respiratory droplets presumed
Temporal pattern Peaks in Sept-Dec and March-May
Communicability Generally limited but higher in some circumstances (e.g., household, child care)
Haemophilus influenzae Type b Epidemiology
Estimated Annual Incidence (per 100,000) of 
Invasive Haemophilus influenzae Type b (Hib) Disease in 
Children Aged <5 Years — United States, 1980–2012
MMWR 2014;63(RR1):1-14.
Haemophilus influenzae, Invasive Disease
Incidence of reported cases (per 100,000), by serotype 
among children aged <5 years — United States, 2000–2013
MMWR 2015;62(53):1-119.
0.27 per 100,000 
Healthy People 2020 Goal





Available 1985-1988 
Not effective in children younger than 18 months of age 
Efficacy in older children varied 
Age-dependent immune response 
Not consistently immunogenic in children 2 years of age and younger 
No booster response 
Haemophilus influenzae Type b Polysaccharide Vaccine 
•



Conjugation improves immunogenicity
Immune response with booster doses
Same polysaccharide capsule linked to different carrier proteins
3 monovalent conjugate vaccines
2 combination vaccines available that contain Hib vaccine
Haemophilus influenzae Type b Conjugate Vaccines

PRP-T
•
•
•
•
•
ActHIB
Hiberix
Pentacel
MenHibrix
PRP-OMP PedvaxHIB
Conjugate Hib Vaccines




Recommended interval 8 weeks for primary series
Minimum interval 4 weeks for primary series
Minimum age 6 weeks
Booster dose at 12-15 months
Hib Vaccine
Vaccine 2 months 4 months 6 months 12-18 months
PRP-T X X X X
PRP-OMP X X NA X
Hib Vaccine Routine  Schedule


Children starting late may not need entire 3 or 4 dose series 
Number of doses child requires depends on current age
See detailed schedule p. 128 of Pink Book, and 2017 catch-up schedule
Unvaccinated Children 7 months of Age and Older 

•
•
•
•

Generally not recommended for persons older than 59 months of age
High-risk older children and adolescents may be vaccinated if not vaccinated in 
childhood
Asplenia
Immunodeficiency 
HIV infection
Receipt of chemotherapy or radiation therapy 
Special populations
Hib Vaccine
Use in Older Children and Adults
High-risk group Hib vaccine guidance
Elective splenectomy If unimmunized: 
1 dose, prior to procedure
Asplenic patient If unimmunized: 1 dose
HIV-infected children If unimmunized: 1 dose
HIV-infected adults Hib vaccination not recommended
Hematopoietic cell transplant 3 doses (at least 4 weeks apart) beginning 6-12 
months after transplant
Guidance for Hib Vaccination in High-risk Groups
•
•
•
•
•
Children aged <24 months with invasive Hib disease
Administer complete series as recommended for child’s age
Vaccinate during the convalescent phase of the illness
 American Indian/ Alaska Natives
PRP-OMP vaccines specifically recommended for primary series doses
Hib disease peaks earlier in infancy
PRP-OMP vaccines produce protective antibody after first dose/early protection 
Special Populations


ActHIB (PRP-T)
Hiberix (PRP-T)
PedvaxHIB (PRP-OMP)
Monovalent Hib Vaccines


Approved for all doses of primary schedule and booster dose
Can be used for previously unvaccinated children per the catch-up schedule
Must be reconstituted only with 0.4% sodium chloride (NaCl) ActHIB diluent
ActHIB (PRP-T)

Approved for all doses of primary schedule and booster dose
Can be used for previously unvaccinated children per the catch-up schedule
Hiberix (PRP-T)
•

Approved for all doses of primary schedule and booster dose
Remember primary series for PRP-OMP vaccines is 2 doses
Can be used for previously unvaccinated children per the catch-up schedule
PedvaxHIB (PRP-OMP)
Hib-containing Combination Vaccines
 
 
Hib-MenCY (MenHIBrix)
DTaP- IPV/Hib (Pentacel)



Contains DTaP, Hib (PRP-T), and IPV
Approved for doses 1 through 4 among children 6 weeks through 4 years of age
Do NOT use for children 5 years or older
Package contains lyophilized Hib (ActHIB) that is reconstituted with a liquid DTaP-IPV 
solution
Pentacel


•
•
Contains Hib (PRP-T) and Neisseria meningitidis serogroups C and Y
Approved for 4 doses between 6 weeks and 18 months of age
Only recommended for routine meningococcal vaccination of infants who are at 
increased risk for meningococcal disease
Persistent complement pathway deficiencies 
Anatomic or functional asplenia, including sickle cell disease
MenHibrix



All monovalent conjugate Hib vaccines are interchangeable for primary series and 
booster dose
3-dose primary series (4 doses total) if more than one brand of vaccine used at 2 or 4 
months of age
Whenever feasible use same combination vaccine for subsequent doses
If vaccine used for earlier doses is not known or not available, any brand may be used 
to complete the series
Hib Vaccine Interchangeability


Severe allergic reactions to vaccine component or following previous dose
Moderate to severe acute illness
Age younger than 6 weeks
Contraindications and Precautions


Swelling, redness, or pain in 5%-30% of recipients
Systemic reactions infrequent
Serious adverse reactions rare
Hib Vaccine Adverse Reactions
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
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Additional Hib Resources
Haemophilus influenzae Disease (Including Hib):  www.cdc.gov/hi-disease/index.html
Hib (Haemophilus influenzae type b) Vaccination:  
www.cdc.gov/vaccines/vpd/hib/index.html
